Studies (all)
|
Study name |
Status |
Echelon level |
Stage |
Age |
Updated |
Included patients |
Active sites |
|
HOVON-associated Transplant BRaVE |
Closed |
n/a |
- |
>=18 |
06-11-2017 |
n/a |
n/a |
|
HOVON-associated SADAL trial (Protocol KCP-330-009) |
Open |
Level A |
2nd line |
>=18 |
05-03-2018 |
n/a |
n/a |
|
HOVON Pomalidomide project |
Open |
n/a |
3rd line |
>18 |
17-11-2015 |
n/a |
n/a |
|
HOVON-associated PLMA25 NK-cell study |
Closed |
n/a |
- |
>= 55 |
29-09-2015 |
n/a |
n/a |
|
HOVON-associated Murano study |
Closed |
n/a |
2nd line |
>= 18 |
31-08-2015 |
n/a |
n/a |
|
HOVON-associated Innate allo-SCT |
Open |
n/a |
- |
>18 |
10-03-2016 |
n/a |
n/a |
|
HOVON-associated GO27878 study (Cavalli study) |
Closed |
n/a |
- |
>=18 |
09-02-2017 |
n/a |
n/a |
|
HOVON-associated CC-122 NHL-001 |
Open |
n/a |
2nd line |
>=18 |
21-04-2016 |
n/a |
n/a |
|
HOVON-associated CARINA (Protocol 54767414LYM2001) |
Closed |
Limited site selection |
3rd line |
>=18 |
07-12-2016 |
n/a |
n/a |
|
HOVON-associated Anti-CD20 cGVHD study |
Closed |
n/a |
- |
>=18 |
09-12-2015 |
n/a |
n/a |
|
HOVON-associated Acerta CL-007 |
Closed |
n/a |
- |
>65 OR >18 - 65 |
23-03-2018 |
n/a |
n/a |
|
HOVON-associated Acerta CL-006 |
Closed |
n/a |
2nd line |
>=18 |
23-03-2018 |
n/a |
n/a |
|
HOVON-associated CMV pp65 specific T-cells |
Open |
n/a |
- |
0 - 75 |
18-10-2012 |
n/a |
n/a |
|
HOVON-associated ACE WM-001 |
Closed |
n/a |
- |
>=18 |
24-12-2015 |
n/a |
n/a |
|
HOVON-associated ACE LY-004 |
Closed |
n/a |
- |
>=18 |
24-12-2015 |
n/a |
n/a |
|
HOVON 900 DLBCL screening |
Open |
|
1st line |
> 18 year |
08-02-2018 |
849 |
64 |
|
HOVON 153 NIVEAU |
Planned |
Level D |
2nd line |
>65 |
19-02-2018 |
n/a |
n/a |
|
HOVON 152 DLBCL |
Planned |
Level D |
1st line |
≥ 18 |
01-02-2018 |
n/a |
n/a |
|
HOVON 151 DLBCL |
Planned |
Level A, Level B, Level C-HIC, Level C-SCT |
1st line |
18 - 75 |
26-02-2018 |
n/a |
n/a |
|
HOVON 149 AL Amyloidosis |
Planned |
n/a |
- |
18 - 70 |
02-03-2018 |
n/a |
n/a |
|
HOVON 148 AML |
Planned |
Level A |
- |
18 - 70 |
25-08-2017 |
n/a |
n/a |
|
HOVON 147 SMM |
Planned |
Level C-HIC |
2nd line |
>=18 years |
22-02-2018 |
n/a |
n/a |
|
HOVON 146 B-ALL |
Planned |
Level A, Level B |
1st line |
18 - 70 |
30-06-2017 |
n/a |
n/a |
|
HOVON 144 NHL |
Planned |
Level D |
2nd line |
18-70 en 71-85 |
03-04-2017 |
n/a |
n/a |
|
HOVON 143 MM |
Open |
Level D |
1st line |
> 18 |
16-03-2018 |
39 |
34 |
|
HOVON 142 CML -SUSTRENIM-CML1415 |
Planned |
Level A, Level B, Level C-HIC & C-SCT |
1st line |
≥18 |
07-06-2017 |
n/a |
n/a |
|
HOVON 141 CLL |
Open |
Level D |
2nd line |
>=18 |
26-03-2018 |
85 |
27 |
|
HOVON 140 CLL |
Open |
Level D |
1st line |
>=18 |
13-03-2018 |
n/a |
34 |
|
HOVON 139 CLL (GIVE) |
Open |
Level D |
1st line |
>=18 |
15-03-2018 |
60 |
25 |
|
HOVON 138 APL (APOLLO) |
Planned |
Limited site selection |
1st line |
18 - 65 years |
18-04-2018 |
n/a |
n/a |
|
HOVON 137 NHL |
Planned |
Level D |
- |
>= 75 |
21-06-2017 |
n/a |
n/a |
|
HOVON 136 NHL |
Open |
Level B |
2nd line |
>18 years |
04-01-2018 |
n/a |
1 |
|
HOVON 135 AML / SAKK |
Open |
Limited site selection |
1st line |
>=66 |
06-12-2017 |
136 |
34 |
|
HOVON 134 MF |
Open |
Level A |
- |
18 - 70 y |
16-04-2018 |
n/a |
n/a |
|
HOVON 133 MCL (TRIANGLE) |
Open |
Level D |
- |
18 - 65 |
18-04-2018 |
n/a |
17 |
|
HOVON 132 AML / SAKK |
Closed |
Limited site selection |
1st line |
18 - 65 |
19-09-2017 |
911 |
52 |
|
HOVON 131 MM / IFM 2015-01 |
Closed |
n/a |
1st line |
18-65 |
18-09-2017 |
n/a |
n/a |
|
HOVON 130 NHL |
Open |
Level D |
1st line |
≥ 18 |
10-04-2018 |
83 |
23 |
|
HOVON 129 PCL |
Open |
Level A |
2nd line |
>18 yrs |
27-02-2017 |
n/a |
13 |
|
HOVON 127 BL |
Open |
Level C-HIC |
1st line |
18-75 |
18-04-2018 |
26 |
22 |
|
HOVON 126 MM |
Closed |
Limited site selection |
1st line |
|
12-12-2016 |
143 |
40 |
|
HOVON 124 WM |
Open |
Limited site selection |
2nd line |
>=18 y |
07-06-2017 |
42 |
21 |
|
HOVON 123 MM |
Closed |
Level D |
1st line |
>= 75 |
29-11-2017 |
240 |
58 |
|
HOVON 121 CLLM1/GCLLSG |
Closed |
Level D |
- |
≥ 18 |
25-07-2016 |
n/a |
4 |
|
HOVON 120 NHL (ZEST) |
Closed |
n/a |
2nd line |
> = 60 |
21-07-2014 |
n/a |
n/a |
|
HOVON 119 MCL |
Open |
Level D |
1st line |
>= 60 |
21-03-2018 |
n/a |
24 |
|
HOVON 117 ALL |
On hold |
n/a |
1st line |
>=55 |
05-08-2016 |
n/a |
1 |
|
HOVON 116 AML |
Closed |
Level A |
1st line |
18 - 70 |
22-11-2017 |
140 |
7 |
|
HOVON 115 Double UCBT |
Closed |
Level A |
- |
|
03-08-2015 |
70 |
6 |
|
HOVON 114 MM |
Open |
Limited site selection |
2nd line |
>= 18 |
02-08-2017 |
n/a |
31 |
|
HOVON 113 MSC |
Open |
Level A, Level B |
2nd line |
Any age |
08-11-2017 |
29 |
7 |
|
HOVON 112 MSC |
On hold |
Level A |
1st line |
Any age |
19-07-2017 |
39 |
2 |
|
HOVON 110 FL |
Open |
n/a |
2nd line |
>= 18 years |
19-04-2018 |
71 |
48 |
|
HOVON 109 CLL |
Closed |
Limited site selection |
1st line |
65 years – 80 years, inclusive; 18 - 64 years, inclusive, with CIRS ≥7 |
04-09-2017 |
63 |
34 |
|
HOVON 108 MM |
Closed |
Level A |
2nd line |
18-65 |
30-09-2013 |
30 |
7 |
|
HOVON 107 MOBILIZATION |
Closed |
Level A |
- |
18-60 |
19-07-2017 |
38 |
4 |
|
HOVON 106 DOUBLE UCBT |
Closed |
n/a |
- |
18-65 |
25-07-2016 |
41 |
5 |
|
HOVON 105 PCNSL / ALLG NHL24 |
Closed |
Level C-HIC |
1st line |
18 - 70 |
26-03-2018 |
200 |
28 |
|
HOVON 104 AL AMYLOIDOSIS |
Closed |
n/a |
1st line |
18-70 |
08-08-2017 |
57 |
18 |
|
HOVON 103 AML |
Open |
Level C-HIC |
1st line |
>=66 |
19-04-2018 |
630 |
29 |
|
HOVON 102 AML |
Closed |
Limited site selection |
1st line |
18 - 65 |
19-07-2017 |
862 |
45 |
|
HOVON 101 CLL/OMB112517 |
Closed |
n/a |
2nd line |
>= 18 |
24-09-2014 |
n/a |
19 |
|
HOVON 100 ALL / EORTC |
Closed |
Level C-SCT |
3rd line |
18 - 70 |
15-08-2017 |
373 |
30 |
|
HOVON-associated MM and haplo |
Open |
n/a |
3rd line |
< 66 yrs |
23-05-2016 |
n/a |
n/a |
|
HOVON 98 / OMB110928 |
Closed |
n/a |
2nd line |
>=18 |
10-04-2014 |
n/a |
n/a |
|
HOVON 97 AML |
Closed |
Level C-HIC |
1st line |
>= 60 |
25-08-2017 |
117 |
25 |
|
HOVON 96 GVHD |
Open |
n/a |
1st line |
18 - 70 |
01-09-2017 |
489 |
7 |
|
HOVON 95 MM |
Closed |
Level D |
1st line |
18-65 |
15-02-2018 |
n/a |
191 |
|
HOVON 93 AML / EBMT |
Closed |
Level B |
1st line |
>= 60 <= 75 |
19-10-2016 |
n/a |
6 |
|
HOVON 92 AML / SAKK |
Closed |
Limited site selection |
1st line |
18 - 65 |
20-10-2014 |
n/a |
n/a |
|
HOVON 91 T-NHL (ACT-2) |
Closed |
n/a |
1st line |
61-80 |
13-05-2014 |
n/a |
n/a |
|
HOVON 90 T-NHL (ACT-1) |
Closed |
n/a |
1st line |
18 - 60 years |
28-04-2014 |
n/a |
n/a |
|
HOVON 89 MDS |
Closed |
Level D |
1st line |
>=18 |
06-04-2018 |
184 |
54 |
|
HOVON 88 CLL |
Closed |
n/a |
2nd line |
18 - 70 |
26-09-2016 |
46 |
18 |
|
HOVON 87 MM |
Closed |
Level D |
1st line |
prev. untreated > 65 or <=65 when inelig. for HDT & PCST |
03-04-2018 |
643 |
101 |
|
HOVON 86 MM |
Closed |
Level C-HIC & C-SCT |
2nd line |
>=18 |
11-03-2015 |
81 |
25 |
|
HOVON 85 NHL |
Closed |
n/a |
2nd line |
>=18 |
12-04-2012 |
61 |
27 |
|
HOVON 84 NHL |
Closed |
n/a |
1st line |
18 - 80 |
05-03-2013 |
585 |
68 |
|
HOVON 82 Sanquin |
Closed |
n/a |
1st line |
>= 18 |
10-06-2009 |
295 |
8 |
|
HOVON 81 AML |
Closed |
n/a |
1st line |
> 60 |
08-10-2012 |
n/a |
n/a |
|
HOVON 80 NHL |
Closed |
n/a |
2nd line |
18 - 65 |
19-09-2014 |
36 |
12 |
|
HOVON 79 APL / PETHEMA LPA 2005 |
Closed |
Level B |
1st line |
18 - 75 |
03-12-2015 |
90 |
11 |
|
HOVON 78 CML |
Closed |
n/a |
1st line |
18 - 65 |
03-05-2010 |
110 |
30 |
|
HOVON 77 NHL |
Closed |
n/a |
1st line |
> 60 |
10-06-2010 |
19 |
24 |
|
HOVON 76 MM |
Closed |
n/a |
1st line |
18 - 66 |
27-11-2012 |
35 |
8 |
|
HOVON 75 MCL |
Closed |
n/a |
1st line |
18 - 65 |
17-12-2012 |
132 |
16 |
|
HOVON 74 ALL |
Closed |
n/a |
2nd line |
18 - 70 |
20-05-2009 |
2 |
8 |
|
HOVON 73 NHL / PRIMA |
Closed |
n/a |
1st line |
>= 18 |
27-10-2014 |
18 |
14 |
|
HOVON 72 AML |
Closed |
n/a |
2nd line |
18 - 60 |
23-05-2008 |
2 |
1 |
|
HOVON 71 ALL |
Closed |
n/a |
1st line |
40 - 70 |
20-04-2012 |
60 |
21 |
|
HOVON 70 ALL |
Closed |
n/a |
1st line |
18 - 39 |
20-04-2012 |
54 |
20 |
|
HOVON 69 T-NHL |
Closed |
n/a |
1st line |
18 - 65 |
01-07-2008 |
20 |
19 |
|
HOVON 68 CLL |
Closed |
n/a |
1st line |
18 - 75 |
19-01-2015 |
274 |
71 |
|
HOVON 67 AML / SAKK |
Closed |
n/a |
1st line |
>= 60 |
23-05-2008 |
6 |
9 |
|
HOVON 66 AML |
Closed |
n/a |
1st line |
18 - 60 |
27-05-2008 |
n/a |
n/a |
|
HOVON 65 MM / GMMG HD4 |
Closed |
n/a |
1st line |
18 - 65 |
01-09-2011 |
828 |
75 |
|
HOVON 64 ITP |
Closed |
n/a |
1st line |
> 18 |
07-05-2010 |
151 |
35 |
|
HOVON 63 NHL |
Closed |
n/a |
1st line |
18 - 65 |
23-05-2008 |
40 |
31 |
|
HOVON 61 NHL |
Closed |
n/a |
1st line |
>= 65 |
23-05-2008 |
n/a |
7 |
|
HOVON 60 MDS / SAKK 33/99 |
Closed |
n/a |
1st line |
> 18 |
23-05-2008 |
6 |
3 |
|
HOVON 59 AML / SAKK / OSHO |
Closed |
n/a |
1st line |
16 - 75 |
23-05-2008 |
22 |
5 |
|
HOVON 58 ET |
Closed |
n/a |
1st line |
18 - 80 |
09-11-2011 |
7 |
9 |
|
HOVON 57 MM |
Closed |
n/a |
1st line |
>= 18 |
22-05-2008 |
24 |
10 |
|
HOVON 55 MCL |
Closed |
n/a |
1st line |
>=65 or 60-65 (see inclusion criteria) |
31-10-2016 |
95 |
30 |
|
HOVON 54 MM |
Closed |
n/a |
1st line |
18 - 65 |
26-07-2010 |
87 |
6 |
|
HOVON 53 AML / OSHO |
Closed |
n/a |
1st line |
50 - 75 |
18-10-2010 |
59 |
10 |
|
HOVON 52 AML |
Closed |
n/a |
1st line |
18 - 75 |
31-12-2013 |
n/a |
n/a |
|
HOVON 51 CML |
Closed |
n/a |
1st line |
18 - 65 |
03-03-2014 |
164 |
16 |
|
HOVON 50 MM |
Closed |
n/a |
1st line |
18 - 65 |
23-08-2016 |
555 |
47 |
|
HOVON 49 MM |
Closed |
n/a |
1st line |
> 65 |
23-08-2016 |
344 |
64 |
|
HOVON 48 NHL / NHLFIT |
Closed |
n/a |
2nd line |
>= 18 |
09-04-2009 |
n/a |
n/a |
|
HOVON 47 NHL |
Closed |
n/a |
1st line |
> 65 |
16-05-2008 |
13 |
39 |
|
HOVON 46 NHL |
Closed |
n/a |
1st line |
>= 65 |
31-12-2013 |
265 |
73 |
|
HOVON 45 MCL |
Closed |
n/a |
1st line |
18 - 65 |
16-05-2008 |
87 |
17 |
|
HOVON 44 NHL |
Closed |
n/a |
2nd line |
18 - 65 |
31-12-2013 |
232 |
24 |
|
HOVON 43 AML |
Closed |
n/a |
1st line |
> 60 |
15-01-2010 |
n/a |
n/a |
|
HOVON 42 A AML / SAKK |
Closed |
n/a |
1st line |
18 - 60 |
19-07-2011 |
514 |
24 |
|
HOVON 42 AML / SAKK |
Closed |
n/a |
1st line |
18 - 60 |
14-05-2008 |
1002 |
4 |
|
HOVON 41 AL Amyloidosis |
Closed |
n/a |
1st line |
< 66 |
28-05-2008 |
70 |
13 |
|
HOVON 40 NHL |
Closed |
n/a |
1st line |
18 - 65 |
04-08-2008 |
93 |
21 |
|
HOVON 39 NHL / EORTC 20981 |
Closed |
n/a |
2nd line |
> 18 |
22-05-2008 |
77 |
32 |
|
HOVON 38 CML |
Closed |
n/a |
1st line |
16 - 65 |
14-05-2008 |
102 |
22 |
|
HOVON 37 ALL |
Closed |
n/a |
1st line |
16 - 59 |
20-07-2011 |
243 |
12 |
|
HOVON 36 MM |
Closed |
n/a |
1st line |
> 64 |
13-05-2008 |
69 |
49 |
|
HOVON 35 NHL / EORTC 20963 |
Closed |
n/a |
1st line |
18 - 66 |
03-06-2008 |
n/a |
n/a |
|
HOVON 34 MDS / EORTC 06961 |
Closed |
n/a |
1st line |
10 - 60 |
13-05-2008 |
n/a |
n/a |
|
HOVON 32 MDS / ELDERLY AML |
Closed |
n/a |
1st line |
15 - 75 |
14-05-2008 |
n/a |
n/a |
|
HOVON 30 AML |
Closed |
n/a |
1st line |
> 18 |
13-05-2008 |
80 |
19 |
|
HOVON 29 AML / SAKK 30/95 |
Closed |
n/a |
1st line |
15 - 60 |
28-05-2008 |
n/a |
n/a |
|
HOVON 27 NHL 94 |
Closed |
n/a |
1st line |
15 - 65 |
22-04-2010 |
n/a |
n/a |
|
HOVON 26 NHL |
Closed |
n/a |
1st line |
15 - 65 |
28-05-2008 |
486 |
72 |
|
HOVON 25 NHL / OG 95-004 |
Closed |
n/a |
1st line |
> 65 |
13-05-2008 |
n/a |
n/a |
|
HOVON 24 MM / OG 96-020 |
Closed |
n/a |
1st line |
< 66 |
13-05-2008 |
n/a |
n/a |
|
HOVON 20 CML |
Closed |
n/a |
1st line |
> 18 |
13-05-2008 |
n/a |
n/a |
|
HOVON 18 ALL |
Closed |
n/a |
1st line |
16 - 60 |
19-04-2018 |
193 |
19 |
|
HOVON-associated MEDI4736-NHL-001 |
Closed |
n/a |
2nd line |
>= 18 |
18-01-2018 |
n/a |
n/a |
|
HOVON-associated MK-3475-087 |
Closed |
n/a |
2nd line |
>=18 |
02-05-2016 |
n/a |
n/a |
|
HOVON-associated GO29365 |
Closed |
Limited site selection |
1st line |
>=18 |
14-10-2016 |
n/a |
n/a |
|